Share your videos with the world

Sign Up | Log In | Help  

   
 
Search // relapsed
Results 1-4 of 4 for ' relapsed ' (0 seconds)
You can tell your friends that you met the REAL queen. You saw the proof in the video. Please show the REAL queen RESPECT! I will be FOREVER your queen. Please BOW down while talking to the REAL queen. Enough said. ROFL . . . . . http://scareykatt.tripod.com/ . . . .
Categories // Funny  Comedy  People and Blog 
Added: 6126 days ago by kattalien
Runtime: 0m25s | Views: 11364 | Comments: 2
   
 

 

 

By reprogramming a 7–year–old girl’s own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom–designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child’s doctors found that she had no evidence of cancer. To view Multimedia News Release, go to http://www.multivu.com/mnr/50777-chop-engineered-immune-t-cell-therapy-anticancer-effect-in-children
Added: 4126 days ago by MultiVuVideos
Runtime: 6m45s | Views: 1339 | Comments: 0
     
 

 

 

Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Categories // People and Blog  Business 
Added: 3450 days ago by MultiVuVideos
Runtime: 1m39s | Views: 847 | Comments: 2
Not yet rated
 

 

 

Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
Categories // Miscellaneous 
Added: 3397 days ago by MultiVuVideos
Runtime: 1m8s | Views: 783 | Comments: 0
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.